Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company. The Company is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).